Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Another Opdivo Disappointment For BMS, This Time In Kidney Cancer

Aug 16 2017

• By Mandy Jackson

Cancer-cells-pink-color_1200x675

Related Content

Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer

Jun 29 2017

Under Fire, Bristol Plans To Pick Up The IO Pieces

Jan 27 2017

Pipeline Watch: Phase III Readouts For Alectinib and Omadacycline

Apr 07 2017

'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Oct 10 2016

What's Next For Bristol's Opdivo/Yervoy Combination

Jun 06 2016

BMS' Opdivo/Yervoy OK'd; 1st U.S. Immuno-Oncology Combo

Oct 02 2015

MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC

Jul 27 2017

Post-MYSTIC, Bristol Renews CTLA-4 Vows, But Is "Not Wedded" In Lung Cancer

Jul 28 2017

Related Companies

Bristol Myers Squibb Company

Roche Holding AG

Genentech, Inc.

Pfizer Inc.

AstraZeneca PLC

Additional Topics

Clinical Trials ImmunoOncology Market Intelligence Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.